vTv Therapeutics Inc - Class A

Research vTv Therapeutics Inc - Class A (VTVT) on Bullrun: market cap USD 142.86M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerVTVT
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 142.86M
• Financial periodFY2025
• Revenue growth-100.0%
• Net income-USD 26.97M

Valuation Snapshot

latest market cap is USD 142.86M.

About vTv Therapeutics Inc - Class A

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases.

Frequently asked questions

What is vTv Therapeutics Inc - Class A's market cap?

vTv Therapeutics Inc - Class A's market capitalization is USD 142.86M.

What does vTv Therapeutics Inc - Class A do?

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases.